Evidence map›Paper›PMID 26437693›Full record

ArticleAmerican journal of hematology2016

Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.

Preetesh Jain, Guilin Tang, Sergej N Konoplev, Rashmi Kanagal-Shamanna, Sa A Wang, Naveen Pemmaraju, Naval Daver, Zeev Estrov

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Preetesh JainM.D. Anderson Cancer Center, Department of Leukemia, the University of Texas, Houston, Texas.
Guilin TangM.D. Anderson Cancer Center, Department of Hematopathology, the University of Texas, Houston, Texas.
Sergej N KonoplevM.D. Anderson Cancer Center, Department of Hematopathology, the University of Texas, Houston, Texas.
Rashmi Kanagal-ShamannaM.D. Anderson Cancer Center, Department of Hematopathology, the University of Texas, Houston, Texas.
Sa A WangM.D. Anderson Cancer Center, Department of Hematopathology, the University of Texas, Houston, Texas.
Naveen PemmarajuM.D. Anderson Cancer Center, Department of Leukemia, the University of Texas, Houston, Texas.
Naval DaverM.D. Anderson Cancer Center, Department of Leukemia, the University of Texas, Houston, Texas.
Zeev EstrovM.D. Anderson Cancer Center, Department of Leukemia, the University of Texas, Houston, Texas.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA-Binding ProteinsLeukemia, B-CellMyelodysplastic SyndromesPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene ProteinsTumor Suppressor Protein p53Aged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone MarrowCytogenetic AnalysisDioxygenasesFemaleHumansIn Situ Hybridization, FluorescenceMutationTreatment OutcomeDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26437693
PMCPMC4764477
OpenAlexW1871250652

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.